However, while the underlying pathogenesis for such adverse ocular events is not clear and likely involves both drug-specific effects as well as a predisposition related to AD and/or pre-existing ocular disorders, the most likely underlying mechanisms for drug-induced ocular inflammation are secondary to IL-13 inhibition, which is common to both medications. Here, IL13 is linked to Alzheimer disease.